Literature DB >> 21402857

Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema.

Brad Moriyama1, Marisa Ditullio, Eleanor Wilson, Stacey A Henning, Scott R Penzak, Robert L Danner, Gennethel Pennick, Michael G Rinaldi, Adrian M Zelazny, Juan Gea-Banacloche, A John Barrett, Thomas J Walsh.   

Abstract

Candida empyema is a serious complication of disseminated candidiasis. However, little is known about the intrapleural pharmacokinetics of echinocandins. We report the penetration of anidulafungin into the pleural fluid of a patient with Candida tropicalis empyema. The anidulafungin ratio for the area under the concentration-time curve from 0 h to the last measurement between pleural fluid and serum values was only 0.125 (12.5%), with pleural fluid concentrations ranging between 0.67 and 0.88 μg/ml.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402857      PMCID: PMC3088219          DOI: 10.1128/AAC.01560-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

2.  Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis.

Authors:  Jean-Baptiste Stern; Philippe Girard; Raffaele Caliandro
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Pericardial and pleural diffusion of voriconazole during disseminated invasive aspergillosis: report of a case with successful outcome.

Authors:  J C Poupelin; F Philit; J C Richard; M Badet; S Lemasson; F Bayle; C Guérin
Journal:  Intensive Care Med       Date:  2006-03-11       Impact factor: 17.440

4.  Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.

Authors:  James A Dowell; Jennifer Schranz; Alice Baruch; Grover Foster
Journal:  J Clin Pharmacol       Date:  2005-12       Impact factor: 3.126

5.  Fungal empyema thoracis: an emerging clinical entity.

Authors:  S C Ko; K Y Chen; P R Hsueh; K T Luh; P C Yang
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

6.  Candida tropicalis empyema associated with acquired gastropleural fistula in a newborn infant.

Authors:  S Malik; G P Giacoia
Journal:  Am J Perinatol       Date:  1989-07       Impact factor: 1.862

7.  Treatment of pleural blastomycosis: penetration of amphotericin B into the pleural fluid.

Authors:  K Kutty; J C Neicheril
Journal:  J Infect Dis       Date:  1987-10       Impact factor: 5.226

8.  Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors:  Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

9.  Penetration of amphotericin B lipid formulations into pleural effusion.

Authors:  Stefan Weiler; Rosa Bellmann-Weiler; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

View more
  7 in total

Review 1.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

2.  Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients.

Authors:  R Welte; P Eller; I Lorenz; M Joannidis; R Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 3.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

4.  A 19-year-old woman with pleuritic chest pain.

Authors:  Faisal A Khasawneh; Mansoor Mehmood; Ruba A Halloush
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Mar-Apr       Impact factor: 2.471

5.  Candida Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes.

Authors:  Suheyla S Senger; George R Thompson; Palash Samanta; Jillian Ahrens; Cornelius J Clancy; M Hong Nguyen
Journal:  Open Forum Infect Dis       Date:  2021-04-17       Impact factor: 3.835

6.  A Case Report of Histoplasma-Associated Empyema Treated With Intravenous Injection and Local Thoracic Irrigation of Amphotericin B Plus Medical Thoracoscopy.

Authors:  Ning Cui; Lijun Wang; Jingming Zhao
Journal:  Front Public Health       Date:  2022-07-06

7.  Candida glabrata Empyema Thoracis-A Post-COVID-19 Complication.

Authors:  Neeraja Swaminathan; Katherine Anderson; Joshua D Nosanchuk; Matthew J Akiyama
Journal:  J Fungi (Basel)       Date:  2022-08-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.